Ovarian Cancer Clinical Trial

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Summary

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has a histologically- or cytologically-confirmed advanced (metastatic and/or unresectable) solid tumor (except breast or ovarian cancers whose tumor has a germline or somatic BRCA mutation) that is not eligible for curative treatment and for which standard of care therapy has failed. Participants must have progressed on or be intolerant to standard of care therapies that are known to provide clinical benefit. There is no limit on the number of prior treatment regimens.
Has either centrally-confirmed known or suspected deleterious mutations in ≥1 of the specified 15 genes involved in HRR or centrally-confirmed HRD based on the Lynparza HRR-HRD assay.
Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology and confirmed in real time by blinded independent central review (BICR). BICR must confirm the presence of radiologically measurable disease per RECIST 1.1 for the participant to be eligible for the study.
Has a life expectancy of ≥3 months.
Must have had CR or PR while on treatment with prior cisplatin or carboplatin, or had CR, PR, or stable disease (SD) while on treatment with prior oxaliplatin (either as monotherapy or in combination) for advanced (metastatic and/or unresectable) solid tumor. Participant must also not have been refractory to prior platinum-containing therapy.
Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1, as assessed within 3 days of study treatment initiation.
Male participants must agree to use contraception during the treatment period and for ≥90 days (3 months) after the last dose of olaparib and refrain from donating sperm during this period.
Female participants must not be pregnant or breastfeeding, and ≥1 of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP who agrees to use contraception during the treatment period and for ≥120 days (3 months) after the last dose of pembrolizumab and 180 days (6 months) after the last dose of olaparib.
Has adequate organ function

Exclusion Criteria:

Has a known additional malignancy that is progressing or has required active treatment in the last 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, ductal carcinoma in situ, or cervical carcinoma in situ that has undergone potentially curative therapy are not excluded.
Has a history of non-infectious pneumonitis/interstitial lung disease that required treatment with steroids or currently has pneumonitis/interstitial lung disease.
Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.
Has an active infection requiring systemic therapy.
Has active tuberculosis (Bacillus tuberculosis [TB]).
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing >10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
Has received colony-stimulating factors (e.g. granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 28 days prior to the first dose of study treatment.
Has a known history of human immunodeficiency virus (HIV) infection.
Has known active hepatitis B or hepatitis C.
Is unable to swallow orally administered medication or has a gastrointestinal (GI) disorder affecting absorption (e.g. gastrectomy, partial bowel obstruction, malabsorption).
Has received prior therapy with an anti-programmed death-1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), or anti-programmed death-ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40 [Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4)], CD137 [tumor necrosis factor receptor superfamily member 9 (TNFRSF9)]).
Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (poly[ADP ribose]) polymerization (PARP) inhibitor.
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to administration of study treatment.
Must have recovered from all adverse events (AEs) due to previous therapies, excluding alopecia, to ≤Grade 1 or Baseline.
Has a known hypersensitivity to the study treatments and/or any of their excipients.
Is currently receiving either strong inhibitors of cytochrome P450 (CYP)3A4 (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate inhibitors of CYP3A4 (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) that cannot be discontinued for the duration of the study. The required washout period prior to starting olaparib is 2 weeks.
Is currently receiving either strong inducers of CYP3A4 (phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate inducers of CYP3A4 (e.g. bosentan, efavirenz, modafinil) that cannot be discontinued for the duration of the study. The required washout period prior to starting olaparib is 5 weeks for phenobarbital and 3 weeks for other agents.
Has received previous allogenic bone-marrow transplant or double umbilical cord transplantation (dUCBT).
Has received a whole blood transfusion in the last 120 days prior to entry to the study.
Has received prior radiotherapy within 2 weeks of start of study treatment.
Is currently enrolled in and receiving study therapy, was enrolled in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks (28 days) of the first dose of study treatment.
The presence of uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, corrected QT interval by Fredericia [QTcF] prolongation >500 msec, electrolyte disturbances), or participant has congenital long QT syndrome.
Has either had major surgery within 2 weeks of starting study treatment or has not recovered from any effects of any major surgery.
Has received a live vaccine within 30 days prior to the first dose of study treatment.
Has had an allogenic tissue/solid tumor organ transplant.

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

300

Study ID:

NCT04123366

Recruitment Status:

Recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 133 Locations for this study

See Locations Near You

The Kirklin Clinic ( Site 0086)
Birmingham Alabama, 35233, United States More Info
Study Coordinator
Contact
205-934-4209
Banner MD Anderson Cancer Center ( Site 0049)
Gilbert Arizona, 85234, United States More Info
Study Coordinator
Contact
480-256-5168
UC Davis Comprehensive Cancer Center ( Site 0039)
Sacramento California, 95817, United States More Info
Study Coordinator
Contact
916-734-6846
San Francisco Oncology Associates ( Site 0085)
San Francisco California, 94115, United States More Info
Study Coordinator
Contact
415-600-1544
University of California San Francisco ( Site 0015)
San Francisco California, 94158, United States More Info
Study Coordinator
Contact
415-885-7604
Banner MD Anderson Cancer Center ( Site 0092)
Greeley Colorado, 80631, United States More Info
Study Coordinator
Contact
970-810-6380
University of Florida ( Site 0078)
Gainesville Florida, 32608, United States
Winship Cancer Institute of Emory University ( Site 0057)
Atlanta Georgia, 30322, United States More Info
Study Coordinator
Contact
404-778-4383
Northeast Georgia Medical Center ( Site 0026)
Gainesville Georgia, 30501, United States More Info
Study Coordinator
Contact
770-219-8822
Northwest Georgia Oncology Centers PC ( Site 0047)
Marietta Georgia, 30060, United States More Info
Study Coordinator
Contact
770-333-2161
Norton Cancer Institute - St. Matthews ( Site 0024)
Louisville Kentucky, 40207, United States
Atlantic Health System ( Site 0046)
Summit New Jersey, 07901, United States
New York Cancer and Blood Specialists-Research Department ( Site 0080)
Port Jefferson Station New York, 11776, United States More Info
Study Coordinator
Contact
631-675-5075
University Hospitals Cleveland Medical Center ( Site 0016)
Cleveland Ohio, 44106, United States
The University of Oklahoma Health Sciences Center ( Site 0050)
Oklahoma City Oklahoma, 73104, United States
Parkland Health & Hospital System ( Site 0091)
Dallas Texas, 75235, United States More Info
Study Coordinator
Contact
214-648-1929
University of Texas, Southwestern Medical Center ( Site 0004)
Dallas Texas, 75390, United States More Info
Study Coordinator
Contact
214-648-1929
University of Texas-MD Anderson Cancer Center ( Site 0087)
Houston Texas, 77030, United States More Info
Study Coordinator
Contact
713-563-1784
Utah Cancer Specialists ( Site 0038)
West Valley City Utah, 84119, United States More Info
Study Coordinator
Contact
801-281-6864
Inova Schar Cancer Institute ( Site 0008)
Fairfax Virginia, 22031, United States More Info
Study Coordinator
Contact
571-472-0633
Northwest Medical Specialties, PLLC ( Site 0007)
Tacoma Washington, 98405, United States
Fundacion CIDEA ( Site 2704)
Ciudad de Buenos Aires Caba, C1121, Argentina More Info
Study Coordinator
Contact
+541149615466
Hospital Britanico de Buenos Aires ( Site 2705)
Ciudad de Buenos Aires Caba, C1280, Argentina More Info
Study Coordinator
Contact
+541143096897
Centro Medico Dra De Salvo ( Site 2702)
Buenos Aires , C1426, Argentina More Info
Study Coordinator
Contact
+5491151082017
CEMIC ( Site 2701)
Buenos Aires , C1431, Argentina More Info
Study Coordinator
Contact
+541152990100
Centro Oncologico Riojano Integral ( Site 2703)
La Rioja , F5300, Argentina More Info
Study Coordinator
Contact
+543804468748
Blacktown Hospital ( Site 2202)
Blacktown New South Wales, 2148, Australia More Info
Study Coordinator
Contact
+61298818421
Tasman Oncology Research Pty Ltd ( Site 2203)
Southport Queensland, 4215, Australia More Info
Study Coordinator
Contact
+61400142592
Monash Health-Monash Medical Centre ( Site 2205)
Clayton Victoria, 3168, Australia More Info
Study Coordinator
Contact
+61395956666
Linear Clinical Research Ltd ( Site 2206)
Nedlands Western Australia, 6009, Australia More Info
Study Coordinator
Contact
+61893463841
BC Cancer-Vancouver Center ( Site 0203)
Vancouver British Columbia, V5Z 4, Canada More Info
Study Coordinator
Contact
6048776000
Moncton Hospital - Horizon Health Network ( Site 0206)
Moncton New Brunswick, E1C 6, Canada More Info
Study Coordinator
Contact
5068575669
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0201)
Montreal Quebec, H2X 1, Canada More Info
Study Coordinator
Contact
514890800024672
Clínica Vida Fundación - Sede Poblado ( Site 2902)
Medellin Antioquia, 05003, Colombia More Info
Study Coordinator
Contact
574 4480016 ext. 2204
Clinica de la Costa S.A.S. ( Site 2900)
Barranquilla Atlantico, 08002, Colombia More Info
Study Coordinator
Contact
+57353369940
Fundacion Cardiovascular de Colombia ( Site 2907)
Piedecuesta Santander, 68101, Colombia More Info
Study Coordinator
Contact
577 6399292 Ext: 306-341-343
Hemato Oncologos S.A. ( Site 2910)
Cali Valle Del Cauca, 76001, Colombia More Info
Study Coordinator
Contact
+5725245839
Fundacion Valle del Lili ( Site 2909)
Cali Valle Del Cauca, 76003, Colombia More Info
Study Coordinator
Contact
+573148883972
CHU Jean Minjoz ( Site 0606)
Besancon Doubs, 25030, France More Info
Study Coordinator
Contact
+33370632256
Institut du Cancer de Montpellier ( Site 0610)
Montpellier Herault, 34298, France More Info
Study Coordinator
Contact
+33467612304
Centre Henri Becquerel ( Site 0607)
Rouen Seine-Maritime, 76038, France More Info
Study Coordinator
Contact
+33232082230
Institut Gustave Roussy ( Site 0602)
Villejuif Val-de-Marne, 94800, France More Info
Study Coordinator
Contact
+33142114336
CHD Vendee ( Site 0604)
La Roche sur Yon Vendee, 85925, France More Info
Study Coordinator
Contact
+33251446161
Universitaetsklinik der Ludwig-Maximilians-Universitaet Muenchen ( Site 0906)
Muenchen Bayern, 81377, Germany More Info
Study Coordinator
Contact
+4989440072250
Universitaetsklinik Koeln ( Site 0903)
Koeln Nordrhein-Westfalen, 50937, Germany More Info
Study Coordinator
Contact
+4922147887009
Charite-Universitaetsmedizin Berlin-Campus Benjamin Franklin ( Site 0902)
Berlin , 12203, Germany More Info
Study Coordinator
Contact
+4930450513383
Oncologika S.A. ( Site 3003)
Guatemala , 01010, Guatemala More Info
Study Coordinator
Contact
+50222790939
Grupo Angeles SA ( Site 3004)
Guatemala , 01015, Guatemala More Info
Study Coordinator
Contact
+50240492110
Sanatorio Nuestra Senora del Pilar ( Site 3006)
Guatemala , 01015, Guatemala
Medi-K Cayala ( Site 3005)
Guatemala , 01016, Guatemala More Info
Study Coordinator
Contact
+50255505555
Centro Medico Integral De Cancerología (CEMIC) ( Site 3002)
Quetzaltenango , 09002, Guatemala More Info
Study Coordinator
Contact
+50259458053
Rambam Health Care Campus-Oncology Division ( Site 0801)
Haifa , 31096, Israel More Info
Study Coordinator
Contact
+97247773003
Hadassah Ein Kerem Medical Center ( Site 0802)
Jerusalem , 91120, Israel More Info
Study Coordinator
Contact
+97226777825
Meir Medical Center ( Site 0804)
Kfar Saba , 44281, Israel More Info
Study Coordinator
Contact
+97297472713
Rabin Medical Center ( Site 0806)
Petah Tikva , 49414, Israel More Info
Study Coordinator
Contact
+97239378076
Chaim Sheba Medical Center ( Site 0800)
Ramat Gan , 52620, Israel More Info
Study Coordinator
Contact
+97235302243
Sourasky Medical Center ( Site 0805)
Tel Aviv , 64239, Israel More Info
Study Coordinator
Contact
+97236973082
Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0703)
Modena Emilia-Romagna, 41124, Italy More Info
Study Coordinator
Contact
+390594224334
ASST Grande Ospedale Metropolitano Niguarda ( Site 0700)
Milano , 20162, Italy More Info
Study Coordinator
Contact
+390264442290
Istituto Nazionale Tumori Fondazione Pascale ( Site 0705)
Napoli , 80131, Italy More Info
Study Coordinator
Contact
+390815903431
Azienda Ospedaliera Universitaria Senese ( Site 0704)
Siena , 53100, Italy More Info
Study Coordinator
Contact
+390432552751
Aichi Cancer Center Hospital ( Site 2504)
Nagoya Aichi, 464-8, Japan More Info
Study Coordinator
Contact
+81-52-762-6111
National Cancer Center Hospital East ( Site 2500)
Kashiwa Chiba, 277-8, Japan More Info
Study Coordinator
Contact
+81-4-7133-1111
Hokkaido University Hospital ( Site 2502)
Sapporo Hokkaido, 060-8, Japan More Info
Study Coordinator
Contact
+81117067061
Kyushu University Hospital ( Site 2506)
Fukuoka , 812-8, Japan More Info
Study Coordinator
Contact
+81-92-641-1151
Okayama University Hospital ( Site 2505)
Okayama , 700-8, Japan More Info
Study Coordinator
Contact
+81-86-223-7151
National Cancer Center Hospital ( Site 2501)
Tokyo , 104-0, Japan More Info
Study Coordinator
Contact
+81-3-3542-2511
Japanese Foundation for Cancer Research ( Site 2503)
Tokyo , 135-8, Japan More Info
Study Coordinator
Contact
+81-3-3520-0111
Seoul National University Bundang Hospital ( Site 2403)
Seongnam-si Kyonggi-do, 13605, Korea, Republic of More Info
Study Coordinator
Contact
+82317877022
Seoul National University Hospital ( Site 2402)
Seoul , 03080, Korea, Republic of More Info
Study Coordinator
Contact
+821090794697
Severance Hospital Yonsei University Health System ( Site 2400)
Seoul , 03722, Korea, Republic of More Info
Study Coordinator
Contact
+82222288132
Samsung Medical Center ( Site 2401)
Seoul , 06351, Korea, Republic of More Info
Study Coordinator
Contact
+82234103438
Daugavpils Regional Hospital ( Site 2104)
Daugavpils , 5417, Latvia
Liepaja Regional Hospital ( Site 2101)
Liepaja , 3414, Latvia
Riga East Clinical University Hospital ( Site 2103)
Riga , 1079, Latvia
P. Stradina Clinical University Hospital ( Site 2102)
Riga , LV-10, Latvia
Preparaciones Oncologicas ( Site 3102)
León Guanajuato, 37178, Mexico More Info
Study Coordinator
Contact
+524777132249
Unidad Biomedica Avanzada Monterrey S. A. ( Site 3108)
Monterrey Nuevo Leon, 64460, Mexico More Info
Study Coordinator
Contact
+528113578896
Centro Medico Zambrano Hellion ( Site 3105)
San Pedro Garza Garcia Nuevo Leon, 66278, Mexico More Info
Study Coordinator
Contact
8188886734
Cuidados Oncologicos ( Site 3104)
Santiago De Quetaro Queretaro, 76000, Mexico More Info
Study Coordinator
Contact
+524422428555
Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 3101)
Madero Tamaulipas, 89440, Mexico More Info
Study Coordinator
Contact
+528331260055
CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 3103)
Ciudad de Mexico , 06100, Mexico More Info
Study Coordinator
Contact
+525555743589
Clinica Integral Internacional de Oncologia S. de R.L. de C.V. ( Site 3107)
Puebla , 72530, Mexico More Info
Study Coordinator
Contact
+522222647166
Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 3206)
Arequipa Ariqipa, 04001, Peru More Info
Study Coordinator
Contact
+51959617508
Hospital Nacional Daniel Alcides Carrion ( Site 3207)
Bellavista Qallaw, 07021, Peru More Info
Study Coordinator
Contact
+51993708246
Hospital Nacional Adolfo Guevara Velasco ( Site 3205)
Cuzco Qusqu, 08003, Peru More Info
Study Coordinator
Contact
+987531715
Oncosalud ( Site 3200)
Lima , 15036, Peru More Info
Study Coordinator
Contact
+51999389433
Instituto Nacional de Enfermedades Neoplasicas ( Site 3201)
Lima , 15038, Peru More Info
Study Coordinator
Contact
+511993473019
Hospital Nacional Arzobispo Loayza ( Site 3208)
Lima , 15082, Peru
Clinica San Gabriel ( Site 3202)
Lima , 15088, Peru
Hospital Nacional Cayetano Heredia ( Site 3203)
Lima , 15102, Peru More Info
Study Coordinator
Contact
+51942 499 515
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warszawa Mazowieckie, 02-78, Poland More Info
Study Coordinator
Contact
+48225463382
Uniwersyteckie Centrum Kliniczne ( Site 1809)
Gdansk Pomorskie, 80-21, Poland More Info
Study Coordinator
Contact
+48585844565
Hematology and Oncology Institute ( Site 0504)
Manati , 00674, Puerto Rico More Info
Study Coordinator
Contact
7878847202
Ad-Vance Medical Research LLC ( Site 0505)
Ponce , 00717, Puerto Rico More Info
Study Coordinator
Contact
7876516697
Pan American Center for Oncology Trials LLC ( Site 0501)
Rio Piedras , 00935, Puerto Rico More Info
Study Coordinator
Contact
7874073333
FDI Clinical Research ( Site 0500)
San Juan , 00927, Puerto Rico More Info
Study Coordinator
Contact
7877221248
Spitalul Judetean de Urgenta Alba Iulia ( Site 1107)
Alba Iulia Alba, 51000, Romania More Info
Study Coordinator
Contact
+400258820825/155
Medisprof ( Site 1102)
Cluj Napoca Cluj, 40064, Romania
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1101)
Cluj-Napoca Cluj, 40001, Romania More Info
Study Coordinator
Contact
0264598361
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103)
Craiova Dolj, 20034, Romania
Policlinica Oncomed SRL ( Site 1104)
Timisoara Timis, 30023, Romania More Info
Study Coordinator
Contact
+40745100495
Universitas Annex National Hospital ( Site 1902)
Bloemfontein Free State, 9301, South Africa More Info
Study Coordinator
Contact
+27514052646
Wits Clinical Research ( Site 1906)
Parktown-Johannesburg Gauteng, 2193, South Africa More Info
Study Coordinator
Contact
+27113390600
Mary Potter Oncology Centre, Little Company of Mary Hospital ( Site 1900)
Pretoria Gauteng, 0181, South Africa More Info
Study Coordinator
Contact
+27123466701
Vaal Triangle Oncology Centre ( Site 1905)
Vereeniging Gauteng, 1930, South Africa More Info
Study Coordinator
Contact
+27164211778
The Oncology Centre ( Site 1904)
Durban Kwazulu-Natal, 4091, South Africa More Info
Study Coordinator
Contact
27 (0)31 208 8666
Cancercare Rondebosch Oncology ( Site 1901)
Rondebosch Western Cape, 7700, South Africa More Info
Study Coordinator
Contact
+27216852578
Hospital Quiron de Madrid ( Site 1301)
Pozuelo de Alarcon Madrid, 28223, Spain More Info
Study Coordinator
Contact
+34902151016
Hospital Clinic i Provincial ( Site 1302)
Barcelona , 08036, Spain More Info
Study Coordinator
Contact
+34932279214
Hospital General Universitario Gregorio Maranon ( Site 1300)
Madrid , 28007, Spain More Info
Study Coordinator
Contact
+34914269519
Skanes Universitetssjukhus Lund. ( Site 2001)
Lund Skane Lan, 221 8, Sweden More Info
Study Coordinator
Contact
+4646177520.
Karolinska Universitetssjukhuset Solna ( Site 2000)
Solna Stockholms Lan, 171 7, Sweden More Info
Study Coordinator
Contact
+46851770000
Akademiska Sjukhuset ( Site 2002)
Uppsala Uppsala Lan, 751 8, Sweden More Info
Study Coordinator
Contact
+46786110000
Baskent University Adana Training Hospital ( Site 1509)
Adana , 01250, Turkey More Info
Study Coordinator
Contact
+905353067506
Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1502)
Ankara , 06100, Turkey More Info
Study Coordinator
Contact
+905334318506
Gazi Universitesi Tip Fakultesi ( Site 1507)
Ankara , 06500, Turkey More Info
Study Coordinator
Contact
00905055873568
Ankara Sehir Hastanesi ( Site 1508)
Ankara , 06800, Turkey More Info
Study Coordinator
Contact
+905555306271
Akdeniz Universitesi Tıp Fakultesi ( Site 1503)
Antalya , 07070, Turkey More Info
Study Coordinator
Contact
+90 242 249 60 00
Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1500)
Edirne , 22030, Turkey
Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1504)
Istanbul , 34098, Turkey More Info
Study Coordinator
Contact
+902124143000
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi ( Site 1505)
Istanbul , 34722, Turkey More Info
Study Coordinator
Contact
+902166065200
Ege Universitesi Tip Fakultesi Tulay Aktas Onkoloji Hastanesi ( Site 1501)
Izmir , 35040, Turkey More Info
Study Coordinator
Contact
0090 232 390 49 08
Necmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 1510)
Konya , 42080, Turkey More Info
Study Coordinator
Contact
+903322236000
Inonu Universitesi Medical Fakultesi ( Site 1506)
Malatya , 44280, Turkey More Info
Study Coordinator
Contact
+90 422 341 06 60
Cherkasy Regional Oncology Dispensary ( Site 1702)
Cherkasy Cherkaska Oblast, 18009, Ukraine
Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 1700)
Dnipro Dnipropetrovska Oblast, 49102, Ukraine
Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Department for daily treated patient (
Ivano-Frankivsk Ivano-Frankivska Oblast, 1932, Ukraine
Communal non profit enterprise Regional Clinical Oncology Center ( Site 1704)
Kharkiv Kharkivska Oblast, 61070, Ukraine
Khmelnitskiy Regional Onkology Dispensary ( Site 1705)
Khmelnitskiy Khmelnytska Oblast, 29009, Ukraine
Kirovograd Regional oncology Dispensary ( Site 1716)
Kropyvnytsky Kirovohradska Oblast, 25011, Ukraine
Medical Centre Consilium Medical ( Site 1712)
Kyiv Kyivska Oblast, 04050, Ukraine
Podillya Regional Center of Oncology ( Site 1708)
Vinnytsia Vinnytska Oblast, 21029, Ukraine
Medical center of the Limited Liability Company Yulis ( Site 1714)
Zaporizhzhia Zaporizka Oblast, 69035, Ukraine
Zhytomyr Regional Oncology Center ( Site 1710)
Zhytomyr Zhytomyrska Oblast, 10002, Ukraine

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

300

Study ID:

NCT04123366

Recruitment Status:

Recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.